Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease

Author(s): Panagiotis Kitrou, Konstantinos Katsanos, Dimitris Karnabatidis, Lazaros Reppas, Elias Brountzos, Stavros Spiliopoulos*

Journal Name: Current Vascular Pharmacology

Volume 15 , Issue 5 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Background: Pharmacotherapy is of increasing interest in peripheral arterial disease (PAD), with novel therapies aiming at different factors contributing to the disease. For antiplatelet therapy, there is no unanimous agreement regarding the nature or duration of optimal antiplatelet therapy so as to reduce major adverse cardiovascular and limb-related events (e.g. repeat interventions and amputations). However, evidence on novel more potent antithrombotic agents, drug combinations and personalized antiplatelet therapy for PAD patients is accumulating. Similarly, statins are now considered as a standard of care in PAD patients, due to their multiple actions which include plaque stabilization, antiinflammatory properties and regression of atheroma.

Conclusion: This review focuses on current evidence available for various antiplatelet regimens and statin therapy for PAD and discusses future perspectives. We consider randomized controlled trials, together with the most important reviews and meta-analyses. Treatment algorithms based on currently available data.

Keywords: Peripheral arterial disease, antiplatelet therapy, aspirin, statins, clopidogrel, cilostazol, ticagrelor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [430 - 445]
Pages: 16
DOI: 10.2174/1570161115666170504124911
Price: $65

Article Metrics

PDF: 41